title: Is There a Relationship between Obstructive Sleep Apnea Syndrome Severity and Nesfatin-1?
abstract: BACKGROUND
  Obstructive sleep apnea syndrome (OSAS) and obesity frequently occur together. The relationship between increased appetite and obesity is well known; however, despite existing knowledge about the relationship between OSAS and obesity, it is not fully understood.
  
  
  OBJECTIVE
  This study aimed to evaluate the relationship between OSAS and the appetite-suppressing hormone nesfatin-1 independent of body mass index (BMI).
  
  
  METHODS
  A total of 134 cases were included in the study; 102 with OSAS (OSAS group) and 32 healthy controls (control group). All cases underwent polysomnography, and nesfatin-1 levels were determined.
  
  
  RESULTS
  Nesfatin-1 levels were significantly lower in the OSAS group compared to the control group (3,776.5 ± 204.8 and 4,056.2 ± 101.5 pg/ml, respectively; p < 0.001). In addition, there was a statistically significant negative correlation between nesfatin-1 and the apnea hypopnea index (r = -0.543; p < 0.001). The statistically significant relationship persisted after adjusting for confounding intergroup factors such as age, gender and BMI (p < 0.001). In the OSAS group, there was a statistically significant correlation between nesfatin-1 and neck circumference (r = -0.304; p = 0.02) but not between nesfatin-1 and BMI and waist circumference. There was no statistically significant difference in nesfatin-1 levels between the sexes.
  
  
  CONCLUSIONS
  OSAS patients have lower nesfatin-1 levels compared to controls, and a greater nesfatin-1 deficit corresponds to an increased severity of OSAS and an increased neck circumference. Replacement therapy may be a potential treatment for obese OSAS patients who have lower nesfatin-1 levels, which may have additional benefits through appetite suppression and weight loss.
authors.affiliation: Department of Pulmonary Diseases, Ataturk University School of Medicine, Erzurum, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Araz
authors.forename: Elif
authors.initials: E
authors.lastname: Yilmazel Ucar
authors.forename: Emrullah
authors.initials: E
authors.lastname: Dorman
authors.forename: Zafer
authors.initials: Z
authors.lastname: Bayraktutan
authors.forename: Muhammed
authors.initials: M
authors.lastname: Yayla
authors.forename: Nafiye
authors.initials: N
authors.lastname: Yilmaz
authors.forename: Hamit
authors.initials: H
authors.lastname: Acemoglu
authors.forename: Zekai
authors.initials: Z
authors.lastname: Halici
authors.forename: Metin
authors.initials: M
authors.lastname: Akgun
mesh_terms: D000328:Adult; D000367:Age Factors; D015992:Body Mass Index; D049628:Body Size; D002135:Calcium-Binding Proteins / Q000097:blood*; D004268:DNA-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009333:Neck; D009419:Nerve Tissue Proteins / Q000097:blood*; D000080866:Nucleobindins; D009765:Obesity / Q000097:blood / Q000150:complications / Q000175:diagnosis; D017286:Polysomnography / Q000379:methods; D012720:Severity of Illness Index; D012737:Sex Factors; D020181:Sleep Apnea, Obstructive / Q000097:blood / Q000150:complications / Q000175:diagnosis; D013223:Statistics as Topic
chemical_list: D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins